AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening

Recruitingn/aAges any - anyAllHeidelberg University
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to further characterize early CF lung disease in newborns, infants and toddlers with cystic fibrosis (CF).

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Newly diagnosed patients with Cystic Fibrosis (CF). Diagnosis of CF: at least one of the following three international accepted criteria is fulfilled: i) sweat chloride ≥ 60mEq/L and/or ii) 2 CF-causing mutations in the CFTR gene and/or iii) changes typical for CF in the transepithelial potential difference in nasal or rectal epithelium. 2. Age and mode of diagnosis: * Early diagnosed (ED): Initial diagnosis following CF-NBS or for other reasons in the first 4 months of life (in preterms corrected age of 4 months) after January 1st, 2006. Other reasons could be prenatal diagnostics, meconium ileus or positive family history. * Late diagnosed (LD): Diagnosed after the fourth month of life due to clinical symptoms; initial diagnosis after January 1st, 2006. Exclusion Criteria: All patients are excluded who themselves or whose parents do not want to participate or that withdraw from the study; or those in whom the diagnosis of CF is unsure. Further exclusion criteria are: 1. Preterms \<30th week of gestation 2. Longer period of mechanical ventilation in first 3 months of life 3. A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol 4. Previous major surgery except for meconium ileus or atresia of the intestine 5. Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to CF 6. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator 7. Chronic lung disease other than CF (e.g. bronchopulmonary dysplasia) 8. History of adverse reaction to medication for sedation or known claustrophobia Criteria, which lead to a displacement of the procedures in sedation until the child has recovered: - Clinically significant upper airway obstruction as determined by investigator (e.g. severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea) \- Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy
💊

What it tests

  • Not listed
📍

Where

4 sites
University Children's Hospital Heidelberg, Cystic Fibrosis Centre
Heidelberg, Germany
University Hospital Gießen and Marburg GmbH
Giessen, Germany
Medizinische Hochschule Hannover
Hanover, Germany
University Children's Hospital Schleswig-Holstein
Lübeck, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy